Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients

Dario Cattaneo, Cristina Gervasoni, Valeria Cozzi, Sara Baldelli, Serena Fucile, Paola Meraviglia, Simona Landonio, Gabriella Boreggio, Giuliano Rizzardini, Emilio Clementi

Research output: Contribution to journalArticlepeer-review


The potential drug-to-drug interaction between darunavir and raltegravir in the setting of HIV infection is a highly debated issue still unresolved. In the present study we have evaluated the pharmacokinetics of darunavir and ritonavir in 53 HIV-1 infected patients with or without concomitant raltegravir administration. The assessment of trough plasma drug concentrations was carried out in all subjects and the potential influence of raltegravir on darunavir and ritonavir disposition, assessed by specific pharmacokinetic evaluations in a subgroup of 25 patients. No significant differences on darunavir and ritonavir plasma trough levels were observed between patients receiving or not raltegravir. Co-administration of raltegravir was, however, associated with a 40% reduction in darunavir C max and estimated AUC 0-24, as well a 60% increase in the estimated darunavir clearance compared with values measured in patients not given raltegravir. Notably, this interaction was independent of the dosage of darunavir and not due to effects of raltegravir on the pharmacokinetics of ritonavir. These results should be taken into account when darunavir-based regimens are implemented in the setting of HIV, especially considering that this drug is usually administered at fixed daily dose and no therapeutic drug monitoring is performed in most centres.

Original languageEnglish
Pages (from-to)198-203
Number of pages6
JournalPharmacological Research
Issue number2
Publication statusPublished - Feb 2012


  • Darunavir
  • Drug-to-drug interactions
  • HIV
  • Pharmacokinetics
  • Raltegravir
  • Ritonavir

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients'. Together they form a unique fingerprint.

Cite this